Keyphrases
Acute Myeloid Leukemia
36%
Advanced Solid Malignancies
10%
Benzoylurea
7%
Cancer Patients
12%
Cisplatin
7%
Clinical Pharmacology
12%
Continuous Infusion
8%
Cytarabine
15%
Cytochrome P450 3A (CYP3A)
12%
Cytochrome P450 3A4 (CYP3A4)
11%
Docetaxel
33%
Dose Escalation
7%
Dose Level
14%
Dose-limiting Toxicity
9%
Drug Interactions
10%
FMS-like Tyrosine Kinase 3 (FLT3)
12%
Gefitinib
10%
Gilteritinib
7%
Glucuronide
10%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
7%
Human Plasma
22%
Imatinib
8%
In Cancer
9%
Irinotecan
8%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
21%
Metabolism
12%
Mouse Plasma
8%
Multikinase Inhibitor
7%
Neutropenia
10%
Nucleoside Analogues
11%
OATP1B1
16%
Paclitaxel
24%
Pharmacodynamics
7%
Pharmacokinetic Profile
7%
Pharmacokinetic Study
29%
Pharmacokinetics
46%
Pharmacologic
10%
Phase I Study
33%
Phase I Trial
9%
Refractory Solid Tumors
9%
Relapsed or Refractory Acute Myeloid Leukemia
11%
Solid Tumors
10%
Sorafenib
31%
Sunitinib
8%
Systemic Exposure
9%
Topotecan
13%
Toxicity Profile
8%
Troxacitabine
9%
Tumor Malignancy
7%
Tyrosine Kinase Inhibitor
15%
Pharmacology, Toxicology and Pharmaceutical Science
Acetonitrile
11%
Acute Leukemia
6%
Acute Myeloid Leukemia
38%
Advanced Cancer
6%
Anticarcinogen
8%
Arylbutyric Acid Derivative
5%
Azacitidine
5%
Bioavailability
6%
Biological Marker
6%
Chemotherapy
7%
Cisplatin
7%
Clinical Pharmacology
8%
CYP3A
11%
CYP3A4
13%
Cytarabine
17%
Cytochrome P450
5%
Decitabine
5%
Disease
12%
Docetaxel
34%
Docosahexaenoic Acid
5%
Doxorubicin
7%
Electrospray Ionization
5%
Elimination
10%
Formate
5%
Gefitinib
8%
Gilteritinib
7%
Glucuronide
10%
High Performance Liquid Chromatography
7%
Imatinib
6%
Irinotecan
8%
Leukemia
10%
Malignant Neoplasm
22%
Maximum Tolerated Dose
6%
Neoplasm
15%
Neutropenia
10%
Nucleoside Analog
11%
Paclitaxel
27%
Pemetrexed
5%
Pharmacodynamics
16%
Pharmacokinetics
100%
Phase I Trials
9%
Phosphotransferase
7%
Protein Tyrosine Kinase Inhibitor
16%
Solid Malignant Neoplasm
26%
Sorafenib
30%
Sunitinib
8%
Taxane
7%
Temozolomide
8%
Topotecan
14%
Troxacitabine
10%